|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
MX9203440A
(es)
|
1985-04-12 |
1992-07-01 |
Genetics Inst |
Proteinas procoagulantes novedosas.
|
|
WO1986006408A1
(en)
|
1985-04-22 |
1986-11-06 |
Genetics Institute, Inc. |
HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX
|
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
|
ATE87663T1
(de)
|
1986-01-03 |
1993-04-15 |
Genetics Inst |
Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
|
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5543502A
(en)
|
1986-06-24 |
1996-08-06 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
|
EP0279582A3
(en)
|
1987-02-17 |
1989-10-18 |
Pharming B.V. |
Dna sequences to target proteins to the mammary gland for efficient secretion
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
IE69026B1
(en)
|
1987-06-12 |
1996-08-07 |
Immuno Ag |
Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
DE122010000006I2
(de)
|
1989-02-21 |
2012-06-21 |
Univ Washington |
Modifizierte formen von fortpflanzungshormonen.
|
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
|
IE922437A1
(en)
|
1991-07-25 |
1993-01-27 |
Idec Pharma Corp |
Recombinant antibodies for human therapy
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
CA2149326C
(en)
|
1992-11-13 |
2007-04-17 |
Mitchell E. Reff |
Fully impaired consensus kozak sequences for mammalian expression
|
|
CA2162271A1
(en)
|
1993-05-26 |
1994-12-08 |
Robert Kotin |
Fusion proteins containing adeno-associated virus rep protein and bacterial protein
|
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
AU5351494A
(en)
|
1993-10-07 |
1995-05-01 |
G.D. Searle & Co. |
Method of producing recombinant eukaryotic viruses in bacteria
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
FR2716893B1
(fr)
|
1994-03-03 |
1996-04-12 |
Rhone Poulenc Rorer Sa |
Virus recombinants, leur préparation et leur utilisation thérapeutique.
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
|
RO120148B1
(ro)
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6291214B1
(en)
|
1998-05-11 |
2001-09-18 |
Glaxo Wellcome Inc. |
System for generating recombinant viruses
|
|
JP2002522013A
(ja)
|
1998-07-24 |
2002-07-23 |
ベイラ、カリッジ、アヴ、メダスン |
部位特異的組換えを使用する迅速なサブクローニング
|
|
JP2002522063A
(ja)
|
1998-08-17 |
2002-07-23 |
アブジェニックス インコーポレイテッド |
増加した血清半減期を有する改変された分子の生成
|
|
US20020065236A1
(en)
|
1998-09-09 |
2002-05-30 |
Yew Nelson S. |
CpG reduced plasmids and viral vectors
|
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
WO2002040544A2
(en)
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US7211395B2
(en)
|
2001-03-09 |
2007-05-01 |
Dyax Corp. |
Serum albumin binding moieties
|
|
WO2002092134A1
(en)
|
2001-05-14 |
2002-11-21 |
Cell Genesys, Inc. |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
CA2457429A1
(en)
|
2001-09-04 |
2003-03-13 |
Francis J. Carr |
Modified factor ix
|
|
US6723551B2
(en)
|
2001-11-09 |
2004-04-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Production of adeno-associated virus in insect cells
|
|
EP1572893B1
(en)
|
2001-11-09 |
2009-01-07 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Production of adeno-associated virus in insect cells
|
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040018557A1
(en)
|
2002-03-01 |
2004-01-29 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2479212A1
(en)
|
2002-03-15 |
2003-09-25 |
Brigham And Women's Hospital, Inc. |
Central airway administration for systemic delivery of therapeutics
|
|
PT1534335E
(pt)
|
2002-08-14 |
2012-02-28 |
Macrogenics Inc |
Anticorpos específicos de fcγriib e processos para a sua utilização
|
|
CA2832136C
(en)
|
2002-09-27 |
2015-11-17 |
Xencor |
Optimized fc variants and methods for their generation
|
|
ATE480562T1
(de)
|
2002-10-15 |
2010-09-15 |
Facet Biotech Corp |
Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
WO2004094642A2
(en)
|
2003-04-24 |
2004-11-04 |
Fondazione Centro San Raffaele Del Monte Tabor |
Lentiviral vectors carrying synthetic bi-directional promoters and uses thereof
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
JP4762156B2
(ja)
|
2004-01-12 |
2011-08-31 |
アプライド モレキュラー エボリューション，インコーポレイテッド |
Ｆｃ領域変異体
|
|
US20080004228A1
(en)
|
2004-03-09 |
2008-01-03 |
Imre Berger |
New Expression Tools for Multiprotein Applications
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
US7598071B2
(en)
*
|
2004-07-09 |
2009-10-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Infectious clone of human parvovirus B19 and methods
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
EP2169072A1
(en)
|
2004-08-23 |
2010-03-31 |
Alnylam Pharmaceuticals, Inc |
Multiple RNA polymerase III promoter expression constructs
|
|
AU2005287047A1
(en)
|
2004-09-17 |
2006-03-30 |
University Of Utah Research Foundation |
Imaging reporters of transgene expression
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
EP1828390B1
(en)
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimeric vectors
|
|
WO2006126972A1
(en)
*
|
2005-05-27 |
2006-11-30 |
Agency For Science, Technology And Research |
Method of delivering nucleic acid molecules into embryonic stem cells using baculoviral vectors
|
|
DK2002003T3
(en)
|
2005-05-27 |
2016-03-21 |
Ospedale San Raffaele Srl |
Gene vector comprising miRNA
|
|
CA2618476A1
(en)
|
2005-08-12 |
2007-02-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
AU2006314843B2
(en)
|
2005-11-17 |
2011-06-30 |
Karolinska Institutet Innovations Ab |
Human bocavirus and methods of diagnosis and treatment
|
|
WO2008016391A2
(en)
*
|
2006-01-31 |
2008-02-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Self-complementary parvoviral vectors, and methods for making and using the same
|
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
|
WO2007140011A2
(en)
|
2006-05-26 |
2007-12-06 |
The Government Of The United States Of America |
Erythroid progenitor cells and methods for producing parvovirus b19 therein
|
|
US7939632B2
(en)
|
2006-06-14 |
2011-05-10 |
Csl Behring Gmbh |
Proteolytically cleavable fusion proteins with high molar specific activity
|
|
EP2423307A1
(en)
|
2006-06-19 |
2012-02-29 |
Catalyst Biosciences, Inc. |
Modified coagulation factor IV polypeptides and use thereof for treatment
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
ES2385679T3
(es)
|
2006-08-24 |
2012-07-30 |
Virovek, Inc. |
Expresión de células de insecto de genes con marcos de lectura abiertos superpuestos, métodos y composiciones de éstos
|
|
WO2008033413A2
(en)
|
2006-09-14 |
2008-03-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
MX2009012343A
(es)
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
|
WO2008141400A1
(en)
|
2007-05-24 |
2008-11-27 |
Medvet Science Pty Ltd |
A novel aetiologic agent of acute gastroenteritis (age), diagnostic methods and therapeutic treatment thereof
|
|
US8563521B2
(en)
|
2007-06-21 |
2013-10-22 |
Technische Universitat Munchen |
Biological active proteins having increased in vivo and/or in vitro stability
|
|
US9115373B2
(en)
|
2007-09-19 |
2015-08-25 |
Uniqure Ip B.V. |
Use of AAV replication machinery for improved protein production
|
|
AU2008311973B2
(en)
|
2007-10-15 |
2013-10-03 |
Cangene Corporation |
Human Factor IX variants with an extended half life
|
|
KR20110015551A
(ko)
|
2008-04-16 |
2011-02-16 |
바이엘 헬스케어 엘엘씨 |
제ｉｘ인자의 부위-지정 변형
|
|
KR20110005862A
(ko)
|
2008-04-16 |
2011-01-19 |
바이엘 헬스케어 엘엘씨 |
변형된 제ｉｘ인자 폴리펩티드 및 이의 용도
|
|
EP2274420A4
(en)
|
2008-04-17 |
2013-09-25 |
Blood Systems Inc |
NEW HUMAN PARVOVIRUS: THE BOCAVIRUS
|
|
EP2268807A2
(en)
|
2008-04-21 |
2011-01-05 |
Novo Nordisk A/S |
Hyperglycosylated human coagulation factor ix
|
|
GB0820631D0
(en)
|
2008-11-11 |
2008-12-17 |
London School Hygiene & Tropical Medicine |
Vectors
|
|
US9938540B2
(en)
|
2008-11-12 |
2018-04-10 |
Ospedale San Raffaele S.R.L. |
Gene vector for inducing transgene-specific immune tolerance
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
MX2011011508A
(es)
|
2009-04-30 |
2012-02-13 |
San Raffaele Centro Fond |
Vector genico.
|
|
US20120134977A1
(en)
|
2009-06-01 |
2012-05-31 |
Yeda Research And Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
|
PE20121539A1
(es)
|
2009-06-08 |
2012-12-06 |
Amunix Operating Inc |
Polipeptidos de la hormona de crecimiento y metodos de preparacion
|
|
WO2010144508A1
(en)
|
2009-06-08 |
2010-12-16 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
GB0911870D0
(en)
*
|
2009-07-08 |
2009-08-19 |
Ucl Business Plc |
Optimised coding sequence and promoter
|
|
EP2292781A1
(en)
|
2009-08-17 |
2011-03-09 |
Genethon |
Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
|
|
CA2771999A1
(en)
|
2009-08-24 |
2011-03-10 |
Amunix Operating Inc. |
Coagulation factor vii compositions and methods of making and using same
|
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
|
US9169494B2
(en)
*
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
EP2534172A2
(en)
|
2010-02-12 |
2012-12-19 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Compositions and methods for preventing or treating a human parvovirus infection
|
|
WO2011112090A2
(en)
|
2010-03-11 |
2011-09-15 |
Amsterdam Molecular Therapeutics (Amt) Ip B.V. |
Method for identifying variant rep protein encoding nucleic acids
|
|
MX375112B
(es)
|
2010-07-09 |
2025-03-06 |
Biogen Hemophilia Inc |
Polipéptidos de factor ix y métodos para usarlos.
|
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
JP6091435B2
(ja)
|
2011-02-22 |
2017-03-08 |
カリフォルニア インスティチュート オブ テクノロジー |
アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
|
|
EP2500434A1
(en)
*
|
2011-03-12 |
2012-09-19 |
Association Institut de Myologie |
Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
|
|
EP2508607A1
(en)
|
2011-04-07 |
2012-10-10 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for liver regeneration and for treatment of liver failure
|
|
HRP20191920T1
(hr)
|
2012-01-12 |
2020-01-10 |
Bioverativ Therapeutics Inc. |
Kimerni polipeptidi faktora viii i njihova uporaba
|
|
EA038705B1
(ru)
|
2012-01-12 |
2021-10-07 |
Биовератив Терапьютикс Инк. |
Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
WO2013123457A1
(en)
|
2012-02-15 |
2013-08-22 |
Biogen Idec Ma Inc. |
Recombinant factor viii proteins
|
|
BR112014020325A2
(pt)
|
2012-02-17 |
2017-08-08 |
Childrens Hospital Philadelphia |
composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
|
|
ES2770501T3
(es)
|
2012-07-11 |
2020-07-01 |
Bioverativ Therapeutics Inc |
Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
|
|
AU2013331000B2
(en)
*
|
2012-10-18 |
2018-04-19 |
Bioverativ Therapeutics Inc. |
Methods of using a fixed dose of a clotting factor
|
|
EP2914731B1
(en)
|
2012-11-01 |
2019-09-11 |
California Institute of Technology |
Reversible gene expression
|
|
CN103215308B
(zh)
|
2013-02-01 |
2015-12-23 |
中国科学院苏州生物医学工程技术研究所 |
表达重组人fviii的整合质粒、细胞株及其构建方法和应用
|
|
RS61387B2
(sr)
|
2013-02-15 |
2024-06-28 |
Bioverativ Therapeutics Inc |
Gen optimizovanog faktora viii
|
|
ES2926798T3
(es)
|
2013-03-15 |
2022-10-28 |
Bioverativ Therapeutics Inc |
Formulaciones de polipéptido de factor VIII
|
|
EP2970966A4
(en)
*
|
2013-03-15 |
2016-10-26 |
Univ North Carolina |
SYNTHETIC ADENOASSOZED VIRUS INVERTED REPEAT SEQUENCES
|
|
AU2014251099B2
(en)
|
2013-04-08 |
2019-01-17 |
The University Of Kansas |
Chimeric adeno-associated virus/ bocavirus parvovirus vector
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US20160311885A1
(en)
*
|
2013-08-14 |
2016-10-27 |
Biogen Ma Inc. |
Recombinant factor viii proteins
|
|
ES2813698T3
(es)
|
2013-09-12 |
2021-03-24 |
Biomarin Pharm Inc |
Vectores de AAV que comprenden un gen que codifica el factor VIII
|
|
EA201691111A1
(ru)
|
2014-01-10 |
2017-01-30 |
Байоджен Ма Инк. |
Химерные белки фактора viii и их применение
|
|
BR112016020688B1
(pt)
|
2014-03-09 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Vetores virais recombinantes, vírus adenoassociado recombinante, composição farmacêutica, bem como uso dos mesmos
|
|
CR20160519A
(es)
*
|
2014-05-13 |
2017-01-27 |
The Trustees Of The Univ Of Pennysylvania |
Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
|
|
US10577627B2
(en)
*
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
GB201420139D0
(en)
|
2014-11-12 |
2014-12-24 |
Ucl Business Plc |
Factor IX gene therapy
|
|
EP3221456B1
(en)
|
2014-11-21 |
2021-09-22 |
University of Florida Research Foundation, Inc. |
Genome-modified recombinant adeno-associated virus vectors
|
|
US11697825B2
(en)
|
2014-12-12 |
2023-07-11 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scAAV
|
|
KR102554850B1
(ko)
|
2015-02-06 |
2023-07-13 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
|
|
WO2016134338A1
(en)
|
2015-02-19 |
2016-08-25 |
University Of Florida Research Foundation, Inc. |
Recombinant aav vectors for gene therapy of human hematopoietic disorders
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
AU2016260401B2
(en)
|
2015-05-14 |
2022-05-19 |
St. Jude Children's Research Hospital, Inc. |
Nucleic acid molecules containing spacers and methods of use thereof
|
|
PE20231949A1
(es)
|
2015-10-30 |
2023-12-05 |
Spark Therapeutics Inc |
VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
IL261524B2
(en)
|
2016-03-03 |
2023-10-01 |
Univ Massachusetts |
End-capped linear double-stranded DNA for non-viral gene transfer
|
|
US12173305B2
(en)
|
2016-05-26 |
2024-12-24 |
University Of Iowa Research Foundation |
cis and trans requirements for terminal resolution of human bocavirus 1
|
|
KR102219859B1
(ko)
|
2016-06-24 |
2021-02-25 |
재단법인 목암생명과학연구소 |
재조합 단쇄 fviii 및 그 화학 접합물
|
|
FR3054841B1
(fr)
|
2016-08-05 |
2021-01-29 |
Centre Nat Rech Scient |
Systeme d'expression baculovirus
|
|
US11142775B2
(en)
|
2017-01-13 |
2021-10-12 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding RNA and uses thereof
|
|
RU2020106730A
(ru)
|
2017-07-14 |
2021-08-16 |
Онкорус, Инк. |
Инкапсулированные полинуклеотиды и способы их применения
|
|
US11549125B2
(en)
|
2017-08-09 |
2023-01-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Closed-ended, linear, duplex adenoassociated virus DNA, and uses thereof
|
|
MX2020001593A
(es)
|
2017-08-09 |
2020-07-13 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y usos de las mismas.
|
|
CA3075168A1
(en)
|
2017-09-08 |
2019-03-14 |
Generation Bio Co. |
Modified closed-ended dna (cedna)
|
|
EP3679148A4
(en)
|
2017-09-08 |
2021-06-09 |
Generation Bio Co. |
LIPID NANOPARTICLE FORMULATIONS FROM NONVIRAL, CAPSID-FREE DNA VECTORS
|
|
KR20200057051A
(ko)
|
2017-09-27 |
2020-05-25 |
시질론 테라퓨틱스, 인크. |
활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소
|
|
JP2021505159A
(ja)
|
2017-12-06 |
2021-02-18 |
ジェネレーション バイオ カンパニー |
修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集
|
|
JP2021511047A
(ja)
|
2018-01-19 |
2021-05-06 |
ジェネレーション バイオ カンパニー |
無細胞合成から得ることができる閉端ＤＮＡベクターおよびｃｅＤＮＡベクターを得るためのプロセス
|
|
AU2019221642A1
(en)
|
2018-02-14 |
2020-07-09 |
Generation Bio Co. |
Non-viral DNA vectors and uses thereof for antibody and fusion protein production
|
|
EP3755803A4
(en)
|
2018-02-22 |
2022-01-19 |
Generation Bio Co. |
CONTROLLED EXPRESSION OF TRANSGENES USING DNA (CEDNA) VECTORS
|
|
CA3092459A1
(en)
|
2018-03-02 |
2019-09-06 |
Generation Bio Co. |
Closed-ended dna (cedna) vectors for insertion of transgenes at genomic safe harbors (gsh) in humans and murine genomes
|
|
CA3092832A1
(en)
|
2018-03-02 |
2019-09-06 |
Generation Bio Co. |
Identifying and characterizing genomic safe harbors (gsh) in humans and murine genomes, and viral and non-viral vector compositions for targeted integration at an identified gsh loci
|
|
EP3762500A1
(en)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
CN112639110A
(zh)
|
2018-06-22 |
2021-04-09 |
阿斯克肋匹奥生物制药公司 |
用于基因递送以在细胞内持续存在的载体
|
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
|
US20220042040A1
(en)
|
2018-09-17 |
2022-02-10 |
Universität Für Bodenkultur Wien |
Dual vector system for improved production of proteins in animal cells
|
|
UY38389A
(es)
|
2018-09-27 |
2020-04-30 |
Sigilon Therapeutics Inc |
Dispositivos implantables para terapia celular y métodos relacionados
|
|
CN120349985A
(zh)
|
2018-10-12 |
2025-07-22 |
建新公司 |
通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生
|
|
WO2020097417A1
(en)
|
2018-11-09 |
2020-05-14 |
Generation Bio Co. |
Modified closed-ended dna (cedna) comprising symmetrical modified inverted terminal repeats
|
|
KR20210119416A
(ko)
|
2019-01-24 |
2021-10-05 |
제너레이션 바이오 컴퍼니 |
폐쇄-말단 dna (cedna), 및 유전자 또는 핵산 치료 관련 면역 반응을 감소시키는 방법에서의 이의 용도
|
|
FR3092522B1
(fr)
|
2019-02-07 |
2021-09-10 |
Rubix S&I |
Système et procédé de nettoyage d’un habitacle de véhicule
|
|
CA3129321A1
(en)
|
2019-02-15 |
2020-08-20 |
Generation Bio Co. |
Modulation of rep protein activity in closed-ended dna (cedna) production
|
|
SG11202108864UA
(en)
|
2019-03-06 |
2021-09-29 |
Generation Bio Co |
Closed-ended dna (cedna) and immune modulating compounds
|
|
KR20210151785A
(ko)
|
2019-03-13 |
2021-12-14 |
제너레이션 바이오 컴퍼니 |
비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
|
|
PL3722434T3
(pl)
|
2019-04-12 |
2022-12-12 |
Freeline Therapeutics Limited |
Układ plazmidowy
|
|
CA3136545A1
(en)
|
2019-04-12 |
2020-10-15 |
Freeline Therapeutics Limited |
Plasmid system
|
|
EP3736286A1
(en)
|
2019-05-09 |
2020-11-11 |
Biotest AG |
Single chain factor viii molecule
|
|
EP3987043A4
(en)
|
2019-06-21 |
2023-07-19 |
Asklepios Biopharmaceutical, Inc. |
PRODUCTION OF VECTORS USING THE PHAGEN REPLICATION ORIGIN
|
|
US20220228171A1
(en)
|
2019-07-17 |
2022-07-21 |
Generation Bio Co. |
Compositions and production of nicked closed-ended dna vectors
|
|
WO2021216975A1
(en)
|
2020-04-23 |
2021-10-28 |
Aav Gene Therapeutics, Inc. |
Aav native-neuro platform and use for neuronal disease gene therapy
|
|
MX2023001109A
(es)
|
2020-07-27 |
2023-04-24 |
Anjarium Biosciences Ag |
Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
|
|
US20220356490A1
(en)
|
2020-08-23 |
2022-11-10 |
Bioverativ Therapeutics Inc. |
Baculovirus expression system
|
|
US20220243201A1
(en)
|
2020-08-23 |
2022-08-04 |
Bioverativ Therapeutics Inc. |
Engineered itr sequences and methods of use
|
|
AU2021330936A1
(en)
|
2020-08-23 |
2023-05-04 |
Bioverativ Therapeutics Inc. |
MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
|
|
AU2022334714A1
(en)
|
2021-08-23 |
2024-04-04 |
Bioverativ Therapeutics Inc. |
Closed-end dna production with inverted terminal repeat sequences
|
|
WO2023028440A2
(en)
|
2021-08-23 |
2023-03-02 |
Bioverativ Therapeutics Inc. |
Baculovirus expression system
|
|
US20230084036A1
(en)
|
2021-08-23 |
2023-03-16 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
JP2024532261A
(ja)
|
2021-08-23 |
2024-09-05 |
バイオベラティブ セラピューティクス インコーポレイテッド |
操作ｉｔｒ配列および使用方法
|